AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
ROCKVILLE, Md., Aug. 31, 2017 -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that it will present at the following September investor conferences:
Citi 12th Annual Biotech Conference
Dates: Wednesday, September 6 – Thursday, September 7
Location: Mandarin Oriental, Boston
Panel: Gene Therapy Manufacturing and Regulatory Opportunities and Challenges; Thursday, September 7, 2017 at 11:00 a.m. ET
Morgan Stanley 15th Annual Global Healthcare Conference
Dates: Monday, September 11 – Wednesday, September 13
Location: Grand Hyatt, New York
Fireside chat: Wednesday, September 13, 2017 at 11:05 a.m. ET
Cantor Fitzgerald Global Healthcare Conference
Dates: Monday, September 25 – Wednesday, September 27
Location: InterContinental New York Barclay Hotel, New York
Company presentation: Tuesday, September 26, 2017 at 4:00 p.m. ET
A live webcast of each presentation can be accessed in the Investors section of REGENXBIO’s website at www.regenxbio.com. An archived replay of each webcast will be available on the same website for approximately 30 days following the presentation. In addition, REGENXBIO senior management will be holding one-on-one meetings at each of the conferences.
About REGENXBIO
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO’s NAV® Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.
CONTACT: Investors Heather Savelle, 646-395-3734 [email protected] Media Adam Pawluk, 202-591-4063 [email protected]
